Navigation Links
Ground Zero Pharmaceuticals Announces Expansion of Global Consulting in Somatic Cell Therapies
Date:10/5/2010

IRVINE, Calif., Oct. 5 /PRNewswire/ -- GZP is pleased to announce that it has expanded its capabilities for strategic regulatory and product development support of gene therapy and somatic cell therapies, including treatment vaccines for cancer and other serious or life-threatening diseases.  New senior associates with expertise in manufacturing and clinical development in these expanding areas allow GZP to provide its clients with hands-on guidance through the FDA regulatory review process.  Firms in the US and Australia have already taken advantage of this expertise and are preparing to launch programs in Phase 1, 2 and 3 clinical trials for their "new concept" products.  Two of our staff, Dr. Chaline Brown and Ms. Tisha Templeton, will be attending and presenting this month at the TRX10 and AusBiotech conferences in Brisbane and Melbourne Australia, respectively, and will be available to discuss these added capabilities.  They will be available for partnering meetings as well.

Specifics of these Australian speaking engagements are:

12 October 2010 – Brisbane – TRX10 – "Regulations Pertinent to Pharmacogenomics and Biomarkers in Europe and USA"

20 October 2010 – Melbourne – AusBiotech 2010 - "Dealing with the FDA – What's Hot?"

GZP continues to believe that early, frequent, and creative communication with the FDA (including informal targeted review of specific issues that can slow down development programs at both early and mid-stages) can lead to more successful medical product development, attracting more funding in today's difficult financial climate.

In 2010, GZP increased its global client base at all phases of development across therapeutic areas such as oncology and neurological disease, and created and submitted several INDs.

Pre-pre-IND, pre-IND and mid-phase meetings with the FDA led to acceleration of drug and biologic development programs for our clients.  Our medical device practice also expanded and included consultation with California's Food and Drug Branch as well as the FDA.

According to Evan Siegel, "We are pleased to see that the need for continued review and approval of key medical products and the determination of our clients to be successful has contributed to the recovery from the global financial crisis across industry.  Our client's dedication, loyalty, their referrals, and the excellence of our staff and associates in maintaining an integrated, cohesive and client-specific approach furthers the commitment of GZP to provide the highest quality ethical and knowledgeable consulting."

Based in Irvine, a major biotechnology center in Southern California, Ground Zero Pharmaceuticals, Inc. is a regulatory affairs and product development consulting firm providing strategic and tactical services to the pharmaceutical, biotechnology and medical device industries.  These include regulatory representation and submissions (paper and electronic), strategic medical consulting, preclinical/nonclinical planning, auditing and review of clinical, nonclinical and CMO sites, medical writing, chemistry, manufacturing and controls consulting, clinical assessment, data management, biostatistics, and project management.  GZP has resources throughout the US, Canada, Australia and Europe, and a wholly owned subsidiary in Brisbane and Melbourne, Australia.

Web Site: http://www.groundzerous.com

For further information please contact Ms. Tisha Templeton, Senior Vice President of Finance and Operations, Ground Zero Pharmaceuticals, Inc., +1-949-852-3666, fax, +1-949-852-3655, ttempleton@groundzerous.com.


'/>"/>
SOURCE Ground Zero Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility
2. SPI Pharma Gains Ground in Roquette Patent Dispute
3. BellBrook Labs Launches Groundbreaking New Microplate for High Content Chemotaxis Assays in a Stable Gradient
4. BioMed Realty Trust Breaks Ground on 176,000 Square Foot R&D Facility for Isis Pharmaceuticals in Carlsbad, California
5. Groundbreaking International Training Lab to Strengthen Food Safety in U.S. and Globally
6. Under new leadership, Kavli Institute at Cornell evolves from a think tank to a proving ground
7. Texas-Based Consortium Announces Project GreenVax: A Groundbreaking Vaccine Manufacturing Research Program
8. Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimers Disease
9. Promise of a New Lupus Treatment Is a Groundbreaking Achievement
10. Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India
11. Grifols Breaks Ground on New National Testing Laboratory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... Prairie, WI (PRWEB) , ... June 23, 2016 ... ... consultancy focused on quality, regulatory and technical consulting, provides a free webinar ... is presented on July 13, 2016 at 12pm CT at no charge. , ...
(Date:6/22/2016)... Research and Markets has announced the addition ... their offering. The global ... billion in 2013. The market is expected to grow at a ... 2020, increasing from $50.6 billion in 2015 to $96.6 billion in ... forecast period (2015 to 2020) are discussed. As well, new products ...
Breaking Biology Technology:
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):